Skip to main content

Cardiovascular outcomes

09-25-2023 | Gestational diabetes | News

Gestational diabetes independently linked to increased future mortality risk

Women with a history of gestational diabetes have a significantly increased risk for long-term mortality regardless of whether or not they subsequently developed type 2 diabetes.

09-20-2023 | Latent autoimmune diabetes of adulthood | News

Latent autoimmune diabetes carries mortality and CVD risks comparable to type 2 diabetes

Latent autoimmune diabetes in adults is associated with similar risks for mortality and cardiovascular disease and an increased risk for retinopathy compared with type 2 diabetes.

08-31-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

06-22-2023 | Cardiovascular outcomes | News

Finerenone modifies CKD-associated CV risk in albuminuric type 2 diabetes

Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

04-24-2023 | Sulfonylureas | News

Sulfonylureas ‘unlikely’ to increase CV, mortality risk in real-world use

Findings from a Scottish national cohort study show that the use of sulfonylureas as second-line glucose-lowering therapy is not associated with elevated cardiovascular risk or all-cause mortality.

03-10-2023 | Primary care | News

COORDINATEd intervention boosts optimal prescribing in type 2 diabetes with ASCVD

A multifaceted, clinic-level intervention results in a marked increase in the proportion of people with type 2 diabetes and atherosclerotic cardiovascular disease receiving appropriate medications, shows the COORDINATE randomized trial.

02-08-2023 | Heart failure | News

Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

12-02-2022 | Nephropathy | News

CKD strongest determinant of post-MI prognosis in type 1 diabetes

The presence of chronic kidney disease has a large impact on the likelihood of people with type 1 diabetes dying after a myocardial infarction, show findings from the FinnDiane Study.